Polyphenols could be Effective in Exerting a Disinfectant-Like Action on Bioprosthetic Heart Valves, Counteracting Bacterial Adhesiveness.

Anti-Microbial Properties Bioprosthetic Heart Valves Infective Endocarditis Polyphenols

Journal

Cardiology and cardiovascular medicine
ISSN: 2572-9292
Titre abrégé: Cardiol Cardiovasc Med
Pays: United States
ID NLM: 101721428

Informations de publication

Date de publication:
2022
Historique:
entrez: 28 10 2022
pubmed: 29 10 2022
medline: 29 10 2022
Statut: ppublish

Résumé

The incidence of infective endocarditis in patients with bioprosthetic heart valves is over 100 times that of the general population with (1) the viability of 9 microorganisms strains (colony-forming units) and the infectivity degree of 3 viral strains (cellular infection capacity) were evaluated after suspension in the polyphenolic solution. (2) Leaflets from a treated and untreated commercial surgical valve model were incubated with a known concentration of (1) The polyphenolic solution proved to be effective in eliminating microorganisms strains guaranteeing the killing of at least 99.9%. The effectiveness is particularly relevant against The data suggest an interesting protective effect against infections and bacterial adhesiveness by a polyphenolic-based solution. Further studies will plan to extend the panel of microorganisms for the evaluation of the anti-adhesive effect; however, the use of optimized polyphenolic blends could lead to the development of new treatments capable to make transcatheter-valve substitutes more resistant to infection.

Sections du résumé

Background UNASSIGNED
The incidence of infective endocarditis in patients with bioprosthetic heart valves is over 100 times that of the general population with
Methods UNASSIGNED
(1) the viability of 9 microorganisms strains (colony-forming units) and the infectivity degree of 3 viral strains (cellular infection capacity) were evaluated after suspension in the polyphenolic solution. (2) Leaflets from a treated and untreated commercial surgical valve model were incubated with a known concentration of
Results UNASSIGNED
(1) The polyphenolic solution proved to be effective in eliminating microorganisms strains guaranteeing the killing of at least 99.9%. The effectiveness is particularly relevant against
Conclusions UNASSIGNED
The data suggest an interesting protective effect against infections and bacterial adhesiveness by a polyphenolic-based solution. Further studies will plan to extend the panel of microorganisms for the evaluation of the anti-adhesive effect; however, the use of optimized polyphenolic blends could lead to the development of new treatments capable to make transcatheter-valve substitutes more resistant to infection.

Identifiants

pubmed: 36303878
doi: 10.26502/fccm.92920287
pmc: PMC9601395
mid: NIHMS1841859
doi:

Types de publication

Journal Article

Langues

eng

Pagination

487-492

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL144125
Pays : United States

Références

PLoS One. 2020 Jan 17;15(1):e0225077
pubmed: 31951610
Clin Microbiol Infect. 2020 Oct;26(10):1368-1374
pubmed: 32036047
J Thorac Cardiovasc Surg. 2019 Feb 20;:
pubmed: 30885626
EuroIntervention. 2019 Aug 09;15(6):e500-e507
pubmed: 31113766
J Ethnopharmacol. 1996 Jan;50(1):27-34
pubmed: 8778504
Eur J Cardiothorac Surg. 2016 Feb;49(2):478-85
pubmed: 25769464
Eur Heart J. 2018 Feb 14;39(7):586-595
pubmed: 29161405
Cardiol Rev. 2019 Sep/Oct;27(5):236-241
pubmed: 31393286
Am J Cardiol. 2018 Dec 15;122(12):2112-2119
pubmed: 30292332
Heart. 2020 Sep;106(18):1413-1419
pubmed: 32471905
Tissue Eng Part A. 2017 Oct;23(19-20):1181-1195
pubmed: 29053434
Clin Microbiol Rev. 2019 Feb 13;32(2):
pubmed: 30760474
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
Eur J Cardiothorac Surg. 2022 Jun 15;62(1):
pubmed: 35211732
BMC Cardiovasc Disord. 2017 Dec 12;17(1):291
pubmed: 29233094
Phytochemistry. 1998 May;48(1):125-9
pubmed: 9621457
J Am Coll Cardiol. 2018 Jun 19;71(24):2744-2752
pubmed: 29903348
J Am Coll Cardiol. 2020 Jun 23;75(24):3020-3030
pubmed: 32553254
Rev Cardiovasc Med. 2020 Mar 30;21(1):123-127
pubmed: 32259911
Ann Thorac Surg. 2020 Jul;110(1):93-101
pubmed: 31794735
Int J Antimicrob Agents. 2011 Aug;38(2):99-107
pubmed: 21514796
Eur Heart J. 2018 Jul 21;39(28):2625-2634
pubmed: 29718148

Auteurs

Filippo Naso (F)

Biocompatibility Innovation SRL, Este, Padua, Italy.

Antonio Maria Calafiore (AM)

Department of Cardiovascular Sciences, Gemelli Molise, Campobasso, Italy.

Mario Gaudino (M)

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, USA.

Peter Zilla (P)

Christian Barnard Department of Cardiothoracic Surgery, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.

Axel Haverich (A)

Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.

Andrea Colli (A)

Cardiac Surgery Unit, Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy.

Robert John Melder (RJ)

Mountain Hawk Consulting LLC, Glen Allen, Virginia, USA.

Alessandro Gandaglia (A)

Biocompatibility Innovation SRL, Este, Padua, Italy.

Classifications MeSH